Investor's Business Daily on MSN
Travere, IBD stock of the day, is on path to $3 billion and in a buy zone
Travere Therapeutics is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone after gapping up on an FDA ...
Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs. He discussed the longstanding challenges of treating ...
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 ...
New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations ...
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results